Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine
29 Juillet 2020 - 7:00AM
Sanofi and GSK agree with the UK government to supply up
to 60 million doses of COVID-19 vaccine
- Agreement relates to vaccine candidate using Sanofi’s
recombinant protein-based technology combined with GSK’s pandemic
adjuvant system
- Both companies are committed to making their COVID-19 vaccine
candidate affordable and available globally
- Ongoing discussions with the European Commission, with France
and Italy on the negotiation team, and other governments to ensure
global access to a novel coronavirus vaccine
PARIS and LONDON – July 29,
2020 – Sanofi and GSK have reached an agreement, subject
to final contract, with the UK government for the supply of up to
60 million doses of a COVID-19 vaccine. The vaccine candidate,
developed by Sanofi in partnership with GSK, is based on the
recombinant protein-based technology used by Sanofi to produce an
influenza vaccine, and GSK’s established pandemic adjuvant
technology.
“With our partner GSK, we are pleased to
cooperate with the UK government as well as several other countries
and global organizations as part of our ongoing efforts to develop
a safe and effective vaccine and make it available as quickly as
possible. We greatly appreciate the UK government’s support of this
shared vision,” said Thomas Triomphe, Executive Vice President and
Global Head of Sanofi Pasteur.
Roger Connor, President of GSK Vaccines added,
"We believe that this adjuvanted vaccine candidate has the
potential to play a significant role in overcoming the COVID-19
pandemic, both in the UK and around the world. We thank the
UK Government for confirmation of purchasing intent, which supports
the significant investment we are already making as a company to
scale up development and production of this vaccine.”
Sanofi is leading the clinical development and
registration of the COVID-19 vaccine and expects a Phase 1/2 study
to start in September, followed by a Phase 3 study by the end of
2020. If the data are positive, regulatory approval could be
achieved by the first half of 2021. In parallel, Sanofi and
GSK are scaling up manufacturing of the antigen and adjuvant to
produce up to one billion doses per year overall.
UK Business Secretary Alok Sharma said: “Our scientists and
researchers are racing to find a safe and effective vaccine at a
speed and scale never seen before. While this progress is truly
remarkable, the fact remains that there are no guarantees.”
“In the meantime, it is important that we secure early access to
a diverse range of promising vaccine candidates, like GSK and
Sanofi, to increase our chances of finding one that works so we can
protect the public and save lives.”
Kate Bingham, Chair of the UK Government’s Vaccines Taskforce,
said: “Through this agreement with GSK and Sanofi, the Vaccine
Taskforce can add another type of vaccine to the three different
types of vaccine we have already secured.
“This diversity of vaccine types is important because we do not
yet know which, if any, of the different types of vaccine will
prove to generate a safe and protective response to
COVID-19. Whilst this agreement is very good news, we mustn’t
be complacent or over optimistic.”
“The fact remains we may never get a vaccine and if we do get
one, we have to be prepared that it may not be a vaccine which
prevents getting the virus, but rather one that reduces
symptoms.”
Sanofi and GSK are committed to making
the vaccine available globally
Active discussions on supply of the vaccine are
ongoing with global organizations, the U.S. and the EU Commission,
with France and Italy on the negotiation team. The partners
plan to provide a significant portion of total worldwide
available supply capacity in 2021/22 to the global initiative,
“Access to COVID‐19 Tools (ACT) Accelerator”, a global
collaboration of leaders of governments, global health
organizations, businesses and philanthropies to accelerate
development, production, and equitable access to COVID-19 tests,
treatments, and vaccines.
On the front lines in the fight against
COVID-19
In addition to the recombinant protein-based
vaccine in collaboration with GSK, Sanofi is also developing a
messenger RNA vaccine candidate in partnership with Translate Bio.
With several innovative vaccine platforms currently being
investigated across the industry, mRNA is considered among the most
promising. Sanofi expects a Phase 1 study to start by the end of
the year, and, if the data are positive, an approval at the
earliest in the second half of 2021. Translate Bio has established
mRNA manufacturing capacity and Sanofi expects to be able to supply
annual capacity of 90 to 360 million doses.
About GSK
GSK is a science-led global healthcare company
with a special purpose: to help people do more, feel better, live
longer. GSK is the leading manufacturer of vaccines globally. For
further information please visit www.gsk.com
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations Contact Ashleigh Koss Tel.: +1
908-981-8745 Ashleigh.Koss@sanofi.com Nicolas Kressmann
Tel.: +1 732-532-5318 Nicolas.Kressmann@sanofi.com
|
Investor
Relations Contact Eva Schaefer-Jansen Tel.: +33 (0)1 53 77
45 45 ir@sanofi.com |
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost
containment initiatives and subsequent changes thereto, and
the impact that COVID-19 will have on us, our customers, suppliers,
vendors, and other business partners, and the financial condition
of any one of them, as well as on our employees and on the global
economy as a whole. Any material effect of COVID-19 on any of
the foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2019. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements. |
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024